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We have analyzed the regulation and expression of ASPP
members, genes implicated in the regulation of the
apoptotic function of the TP53 tumor-suppressor gene,
in acute lymphoblastic leukemia (ALL). Expression of
ASPP1 was significantly reduced in ALL and was
dependent on hypermethylation of the ASPP1 gene
promoter. Abnormal ASPP1 expression was associated
with normal function of the tumor-suppressor gene TP53
in ALL. The analyses of 180 patients with ALL at
diagnosis showed that the ASPP1 promoter was hyper-
methylated in 25% of cases with decreased mRNA
expression. Methylation was significantly higher in adult
ALL vs childhood ALL (32 vs 17%, P¼ 0.03) and T-ALL
vs B-ALL (50 vs 9%, P¼ 0.001). Relapse rate (62 vs
44%, P¼ 0.05) and mortality (59 vs 43%, P¼ 0.05) were
significantly higher in patients with methylated ASPP1.
DFS and OS were 32.8 and 33.7% for patients with
unmethylated ASPP1 and 6.1 and 9.9% for methylated
patients (Po0.001 y Po0.02, respectively). On the
multivariate analysis, methylation of the ASPP1 gene
promoter was an independent poor prognosis factor in
ALL patients. Our results demonstrate that decreased
expression of ASPP1 in patients with ALL is due to an
abnormal methylation of its promoter and is associated
with a poor prognosis.
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Introduction
TP53, a tumor-suppressor gene located in the short arm
of chromosome 17, is the most frequently mutated gene
in human cancer. The gene product is a 393 amino-acid
nuclear phosphoprotein that regulates different cellular
processes such as gene transcription, DNA synthesis,
DNA repair, cell cycle arrest, senescence and apoptosis.
Mutations of TP53 may result in an inhibition of
protein function, which is associated with tumor
progression and genetic instability (Caron de Fromentel
and Soussi, 1992; Hollstein et al., 1994; Soussi et al.,
1994). Although 40–50% of human tumors have
mutations on TP53, the percentage of mutations in
patients with leukemia is significantly lower (less that
10%), suggesting that other mechanisms may be
involved in the inability of p53 to induce apoptosis
since p53 does not suppress tumor growth or induce
apoptosis in tumors with wild-type TP53.
The recently described ASPP family of proteins
comprised of ASPP1, ASPP2 and iASPP has been
implicated in the apoptotic function of TP53 and p53
family members TP73L (p63) and TP73 (Bergamaschi
et al., 2004). Different studies have shown that ASPP1
and ASPP2 increase the apoptotic effect of p53 by
inducing the transcription of proapoptotic genes such as
BAX and PIG3 mediated by TP53, while they have no
influence on the transcription of MDM2 and CDKN1A
(p21, Cip1), which mediate p53-dependent cell cycle
arrest (Samuels-Lev et al., 2001; Slee and Lu, 2003;
Bergamaschi et al., 2004). Transactivation of TP53-
mediated transcription of proapoptotic genes mediated
by ASPP1 and ASPP2 is completely abolished by
increased expression of the evolutionary conserved
TP53 inhibitor and third member of the ASPP family,
iASPP (Bergamaschi et al., 2003).
It has been hypothesized that in wild-type TP53
tumors, alterations of ASPP1 and/or ASPP2, can
produce a selective advantage due to the lack of
stimulation of apoptosis (Samuels-Lev et al., 2001; Slee
and Lu, 2003; Bergamaschi et al., 2004). Samuels-Lev
et al. (2001) studied the mRNA expression levels of
ASPP1 and ASPP2 in breast cancer samples with wild-
type TP53, showing that the level of ASPP1 and ASPP2
mRNA was downregulated in 60 and 22.5% of samples,
respectively (Samuels-Lev et al., 2001). Recently, Liu
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et al. (2004) have analyzed the mRNA expression levels
of ASPP family members in three leukemia cell lines and
Zhang et al. (2005) have studied the expression of
iASPP mRNA in acute leukemias. These analyses have
shown a downregulation of ASPP1 and an upregulation
of iASPP mRNA levels, suggesting that alterations of
ASPP could be an important step in the pathogenesis of
hematological neoplasm (Liu et al., 2004; Zhang et al.,
2005).
Aberrant DNA methylation has been established as
an essential and major epigenetic mechanism that
participates in the regulation and inactivation of gene
expression and induction of tumorigenesis (Bird, 2002;
Esteller, 2002). Several reports have shown abnormal
hypermethylation in the promoter region of genes
involved in cell cycle control, apoptosis, cell–cell
adhesion and DNA repair in human leukemias and we
have demonstrated that abnormal methylation of the
promoter of a number of genes is common in patients
with acute lymphoblastic leukemia (ALL) (Roman-
Gomez et al., 2003, 2004a, b; Rossi et al., 2004), which
is associated with the inappropriate transcriptional
silencing of these genes and represents an alternative
mechanism to gene mutations and deletions.
The abnormal expression of members of the ASPP
family in leukemic cell lines, the presence of a CpG
island in the promoter region of ASPP1 and ASPP2 as
well as the fact that abnormal methylation of the
promoter of a number of genes is common in patients
with ALL, led us to study the role of ASPP1, ASPP2,
iASPP and their relation with TP53 in the pathogenesis
of ALL. We have analyzed if expression of ASPP1 and
ASPP2 is regulated epigenetically by abnormal promo-
ter hypermethylation and whether this expression is
associated with prognosis in patients with ALL.
Results
Regulation of ASPP1, ASPP2 and iASPP expression in
tumor cell lines
We initially examined the expression of ASPP1, ASPP2
and iASPP in a number of ALL cell lines by Q-RT-
PCR. No ASPP1 expression was observed in B-
precursor ALL cell lines (MY, NALM-20 and TOM-
1). A reduced expression was observed in two T-cell
ALL cell lines (JOURKAT and MOLT-4), whereas the
LOUCY T-ALL cell line showed normal levels of
ASPP1 expression (Table 2 and Figure 1b). Expression
of ASPP2 and iASPP was not altered in ALL (data not
shown).
As the promoters of ASPP1 and ASPP2 contain a
typical CpG island showing >60% CþG content and
an observed-overexpected CpG frequency of >0.6 we
decided to analyze their methylation status. By MSP,
the ASPP1 promoter was revealed to be highly
methylated in ALL cell lines lacking ASPP1 expression
(TOM-1, NALM-20 and MY) (Figure 1a), which was
clearly in contrast with the lack of ASPP1 promoter
methylation observed in normal cells as well as CML,
breast and lung carcinoma-derived cell lines (data not
shown). Methylation of the ASPP1 promoter was
further demonstrated by bisulfite sequencing of different
clones obtained after cloning MSP products, which
showed a complete concordance with MSP results
(Figure 1c). While bone marrow DNA from a healthy
donor showed a nonmethylated ASPP1 promoter,
sequencing of human male genomic DNA universally
methylated and NALM-20 (ASPP1 promoter hyper-
methylation by MSP and lack of ASPP1 expression by
PCR) showed a complete methylation throughout the
entire region analyzed. In ALL-derived LOUCY cell
line, which had a nonmethylated ASPP1 promoter by
MSP and normal ASPP1 mRNA expression, sequen-
cing analysis revealed an unmethylated pattern with
methylation of only a few individual CpG sites
(Figure 1c).
Exposure of ALL cell lines to the demethylating agent
5-Aza-20-deoxycytidine restored expression of ASPP1
mRNA in cell lines that showed hypermethylation of the
ASPP1 promoter such as MY, NALM-20 and TOM-1
(Figure 1d) but had no effect on ASPP1 mRNA
expression in nonmethylated ALL-derived JOURKAT,
MOLT-4 and LOUCY cell lines. Furthermore, treat-
ment of ALL-derived NALM-20 cells with 2 mM of 5-
Aza-20-deoxycytidine was associated with the presence
of both the methylated (ASPP1-1/ASPP1-2) and un-
methylated (ASPP1-3/ASPP1-4) MSP product while
MSP analysis performed with DNA of NALM-20 cells
treated with 4 mM of 5-Aza-20-deoxycytidine showed
only the methylated MSP product (Figure 1e), along
with the upregulation of ASPP1 mRNA. These results
indicate that hypermethylation is a major mechanism
through which ASPP1 expression is silenced in ALL
cells (Figure 1 and Table 2). As expected, from the
ASPP2 expression analysis, we did not find an abnormal
methylation pattern of the ASPP2 promoter (data not
shown).
While TOM-1 and MY cell lines presented both the
methylated and unmethyated allele, the NALM-20 cell
line had only the methylated form. To determine
whether complete lack of ASPP1 expression in
NALM-20 was due to hypermethylation of both
promoters or to other mechanisms we analyzed the
possibility of gene deletions by Fluorescence in situ
hybridization (FISH). FISH analysis using 1 BAC
covering the ASPP1 gene demonstrated that a deletion
of ASPP1 was present in NALM-20 and in a
subpopulation of TOM-1 cell line, suggesting that
complete lack of expression of ASPP1 in the NALM-
20 cell line can be due to methylation of one allele and
deletion of the other one (Figure 2).
Analysis of TP53 mutation, deletion and promoter
methylation in ALL cell lines
Although TP53 is frequently mutated in a number of
tumors this is not the case in ALL where the frequency
of TP53 mutations is lower than 10%. Abnormal
expression of ASPP1, in the context of functional
TP53 would suggest a potential role for ASPP1 in ALL
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resistance to apoptosis. So, to determine whether TP53
was functional in our ALL cells lines (TOM-1, NALM-
20, MY, LOUCY and TANOUE cell lines) we examined
the presence of mutation or deletion of TP53 or
abnormal methylation of its promoter region. Mutation
analysis by DGGE showed an aberrant electrophoretic
pattern only in the LOUCY cell line that did not present
an aberrant methylation of the ASPP1 promoter
Figure 1 ASPP1 expression and promoter methylation in ALL-derived cell lines: (a) Methylation-specific PCR. UC indicates
unmethylated control (DNA of marrow mononuclear cells from a healthy donor), MC indicates methylated control and NC indicates
negative PCR control. ALL-derived cell lines: TOM-1, NALM-20, MY, LOUCY and TANOUE; (b) Analysis of the mRNA
expression of ASPP1 in ALL-derived cell lines and patient samples (ALL-1 and ALL-2). ALL-derived cell lines: TOM-1, NALM-20,
LOUCY and TANOUE. ABL1 mRNA amplification was used to assess RNA integrity and as reference gene; (c) Sequence analysis of
the ASPP1 promoter region after bisulfite modification. The black box indicates the methylated cytosine while the white box indicates
the unmethylated cytosine in the dinucleotide CpG. UC indicates unmethylated control (DNA of marrow mononuclear cells from a
healthy donor) and MC indicates methylated control. ALL-derived cell lines: NALM-20 and LOUCY. 1: genomic sequence of the
ASPP1 promoter region; 2: methylated sequence of the ASPP1 promoter region after bisulfite modification and 3: unmethylated
sequence of the ASPP1 promoter region after bisulfite modification. (d) Analysis of ASPP1 mRNA expression in MY, TOM-1 and
NALM-20 ALL-derived cell lines after treatment with 4 mM of 5-Aza-20-deoxycytidine. ABL1 mRNA amplification was used to assess
RNA integrity and as a reference gene. (e) Methylation specific PCR in ALL-derived NALM-20 cell line after treatment with 4 mM
of 5-Aza-20-deoxycytidine.
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(Supplementary Figure S1). Sequencing of TP53 exon 8
of the LOUCY cell line showed that this aberrant
electrophoretic pattern corresponds to a previously
described V272M (GTG-ATG) missense mutation in
exon 8 (Supplementary Figure S1B). Abnormal methy-
lation was not detected either in the CpG dinucleotide
(Hpa II/Msp I) or in the CC(A/T)GG (Eco RII/Bst NI)
motifs in any of the ALL-derived cell lines (Supplemen-
tary Figure S2).
FISH analysis performed using a RPCI-11 199F11
BAC clone, that covers TP53 gene, and one alphoide
probe, that covers the chromosome 17 centromere,
showed a normal hybridization pattern (two red –
RPCI-11 199F11 BAC clone - and two green signals –
chromosome 17 centromere-) in TOM-1 and deletion of
one allele of TP53 in the NALM-20 cell line (one red
and two green signals). Two different clones were
identified in the TANOUE and LOUCY cell lines.
While the most frequent clone in the TANOUE cell line
did not show an abnormal signal, a second clone had
three red and three green signals that corresponded to
three complete chromosomes 17. Similarly, we found
one clone with four red and four green signals and a
second one with three red and four green signals in the
LOUCY cell line, corresponding to a deletion of one of
the four TP53 alleles present in this cell clone
(Supplementary Figure S3).
Methylation and downregulation of ASPP1 mRNA
is associated with poor prognosis in patients with B
and T-ALL
In order to determine the prognostic value of ASPP1 in
patients with ALL, we analyzed the mRNA expression
and promoter methylation in a group of 180 patients.
ASPP1 methylation was detected at diagnosis in 25%
(45/180) of patients with adult or childhood ALL of all
the FAB subtypes. In all these patients a downregula-
tion of ASPP1 expression was observed. In contrast,
decreased ASPP1 expression was detected in only 18 of
135 ALL patients with an unmethylated promoter
(13%).
As shown in Table 1, aberrant ASPP1 methylation
was more frequently observed in adults than in children
(32 vs 17%, P¼ 0.03) and also in T-cell ALL than in
precursor-B ALL (50 vs 9%, P¼ 0.001). Other clinical
and laboratory features did not differ significantly
between methylated and nonmethylated patients. Poor-
risk cytogenetic or molecular events, risk groups
according to both NCI or ‘Programa para el estudio y
tratamiento de las hemopatias malignas’ (PETHEMA)
classifications, good risk features (hyperdiploidy and
TEL-AML1 fusion), type of PETHEMA protocol
administered and number of patients who received stem
cell transplantation were similarly distributed between
the two groups defined by ASPP1 promoter methyla-
tion. Separate analysis of adult and childhood ALL
patients gave the same results as the global series.
Table 1 details the relapse history, CR rates and
mortality for patients who exhibited ASPP1 methyla-
tion and the equivalent data for patients with the normal
ASPP1 gene. CR rates of patients with the normal and
methylated ASPP1 gene were 91 and 85%, respectively,
accounting for an 88% overall CR rate. This suggests
that methylation of the ASPP1 gene promoter did not
correlate with response to remission induction therapy.
However, patients with abnormal methylation of the
ASPP1 promoter had a higher relapse (62 vs 44%,
P¼ 0.05) and mortality rate (59 vs 43%, P¼ 0.05) than
nonmethylated patients.
We finally analyzed DFS among patients who
achieved CR according to ASPP1methylation (Table 2).
Estimated DFS rates at 6 years were 32.8 and 6.1% for
normal and methylated patients, respectively (P¼ 0.001)
(Figure 3a). Among children with unmethylated ASPP1
promoter, the 6 years DFS was 45.4% contrasting with
13.9% for children with hypermethylated ASPP1
promoter (P¼ 0.006, Figure 3b). Among adult ALL
patients, the 3-years DFS was 0% for methylated cases
and 35.7% for unmethylated cases (P¼ 0.1, Figure 3c).
The actuarial OS calculated for all leukemic patients was
33.7 and 9.9% at 10 years for cases with the
unmethylated and hypermethylated ASPP1 gene pro-
moter, respectively (P¼ 0.02, Figure 4a). Among child-
hood ALL patients, the 10-years OS was 34.8% for
methylated cases and 47.8% for unmethylated cases
(P¼ 0.08, Figure 4b).
A multivariate analysis of potential prognostic factors
(including the type of PETHEMA protocol applied)
demonstrated that methylation of the ASPP1 gene
NALM-20 TOM-1 (A) TOM-1 (B)
Figure 2 FISH analysis of ASPP1 gene in NALM-20 and TOM-1 cell lines. RP11-73M18 probe that covers the ASPP1 was labeled
with Spectrum Oranges (red signal), RP11-600F24 probe centromeric to ASPP1 with Spectrum Greens (green signal), and alphoide
probe located in chromosome 14 and 22 centromeres with DEAC (light blue signal).
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promoter was an independent prognostic factor for DFS
in the global series and also in childhood ALL (Table 3).
Discussion
The recent identification of ASPP proteins as key
regulators of p53 function has significantly contributed
to understanding why despite normal p53 function,
some tumor cells are able to escape from p53-induced
apoptosis after DNA damage (Samuels-Lev et al., 2001;
Bergamaschi et al., 2004). Although recent studies have
Table 1 Clinical characteristics and outcome of 180 ALL patients
according to ASPP1 gene methylation status
Feature Nonmethylated
(n¼ 135) %
Methylated
(n¼ 45) %
P-value
Age 0.03
o15 years 83 17
>15 years 68 32
Sex (M/F) 64/36 72/28 NS
WBC NS
o50 109/l 78 70
>50 109/l 22 30
FAB classification NS
L1 38 25
L2 50 64
L3 12 11
Blast lineage 0.001
B cell 91 9
T cell 50 50
NCI risk groups NS
Standard 80 65
Poor 20 35
PETHEMA risk
groups
NS
Standard 40 34
Poor 60 66
Treatment NS
PETHEMA 89 25 27
PETHEMA 93 75 73
BMT 19 10 NS
Best response
CR 91 85 NS
Cytogenetic/
molecular
abnormalities
NS
BCR-ABL 17 14
t(1;19) 4 2
11q23 3 3
c-myc 6 8
7q35-14q11 6 8
Hyperdiploidy 9 5
TEL-AML1 5 3
Normal 46 52
Others 3 3
NT 1 2
Relapse 44 62 0.05
Death 43 59 0.05
Data are expressed as percentages; WBC¼white blood count;
FAB¼French-American-British; NCI¼National Cancer Institute;
PETHEMA¼Programa para el estudio y tratamiento de las hemopatias
malignas; BMT¼ bone marrow transplantation; CR¼ complete remis-
sion. NT¼ nontested.
Table 2 ASPP1 promoter methylation and mRNA expression in B/
T-precursor ALL cell lines
Cell line ASPP1 methylation NASPP1 (%) NASPP1+AZA (%)
TOM-1 YES 0 70.5
NALM-20 YES 0 108
MY YES 0 98
JOURKAT NO 50.5 77
MOLT-4 NO 40.5 30
LOUCY NO 102 130
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Figure 3 Kaplan–Meier survival curves for ALL patients. DFS
curves according to the methylation profile. (a) All patients
enrolled in this study. (b) Childhood ALL. (c) Adult ALL.
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demonstrated a downregulation of ASPP1 mRNA with
upregulation of iASPP in leukemic cell lines (Liu et al.,
2004; Zhang et al., 2005), our results describe for the
first time that a significant percentage of patients with
ALL have a decreased expression of ASPP1; that lack of
expression is due to hypermethylation of the gene
promoter and, more importantly, that hypermethylation
and downregulation of ASPP1 expression is, signifi-
cantly and independently of other prognostic factors,
associated with poor prognosis with a reduced DFS and
OS both in children and adult ALL.
The initial isolation of ASPP1 and ASPP2 proteins
was performed based on two hybrid screening systems
using p53 and bcl-2 as baits (Iwabuchi et al., 1994;
Naumovski and Cleary, 1996). These studies identified
two proteins 53BP2 and Bbp that are now recognized as
truncated forms of ASPP2 (C-terminal 529 amino acids
and the truncation of 123 amino acid at the N-terminal,
respectively). The fact that the initial studies were
performed with the truncated forms further added some
confusion to their physiological role as the results were
sometimes contradictory (Gorina and Pavletich, 1996;
Iwabuchi et al., 1998; Lopez et al., 2000; Mori et al.,
2000; Ao et al., 2001). However, a more detailed and
clear description of their structure and function has only
recently been performed along with isolation of the third
member of the family, an inhibitor of p53 function
iASPP (Samuels-Lev et al., 2001; Bergamaschi et al.,
2003). The relevance of these proteins in tumorigenesis
stems from the fact that they regulate p53 function by
transactivating p53 transcription of proapoptotic genes
and also by directly stimulating the proapoptotic
activity of p53. Abnormal expression of ASPP members
has been described in breast cancer where ASPP1 and
ASPP2 are downregulated in 60 and 23% of tumors,
respectively (Samuels-Lev et al., 2001). Interestingly,
downregulation of ASPP1 and ASPP2 is more fre-
quently detected in breast cancer samples from patients
with unmutated p53 further substantiating how tumors
are able to arise even in the presence of wild-type p53. In
lung cancer cell lines, downregulation of 53BP2 has also
been associated with resistance to chemotherapy-
induced apoptosis (Mori et al., 2000).
Along the same lines, we have described that 38% of
patients with newly diagnosed ALL show a down-
regulation of ASPP1 and have demonstrated that
expression of ASPP1 is controlled epigenetically by
methylation of gene promoter both in ALL cell lines and
also in patient’s primary cells. However, no promoter
hypermethylation was observed in other type of tumors
such as CML, lung or breast cancer. As we have
described previously, methylation controls the expres-
sion of a number of genes in patients with ALL where
we have demonstrated that the methylation profile is
associated with disease prognosis and survival (Roman-
Gomez et al., 2004b). Besides prognostic significance,
methylation of ASPP1 could also be especially relevant
in that it could help to explain why tumors with normal
p53 have a selective advantage as cells are resistant to
apoptosis. Although we did not perform functional
studies in our cell lines, lack of p53 mutation, methyla-
tion and deletion in cell lines with otherwise abnormal
ASPP1 expression indicates that resistance to apoptosis
in these cell lines might be dependent on ASPP1. One
exception deserves further comment: the NALM-20 cell
line had a total lack of expression of ASPP1 and also a
lack of amplification of the unmethylated allele, unlike
other cell lines such as TOM-1 in which both the
unmethylated and methylated allele were amplified by
PCR (Figure 1a). FISH analysis of ASPP1 in NALM-20
demonstrated that there was a deletion of ASPP1
suggesting that at least in this cell line, complete absence
of ASPP1 is dependent on deletion of one allele and
methylation of the other.
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Figure 4 Kaplan–Meier survival curves for ALL patients. OS
curves according to the methylation profile. (a) All patients
enrolled in this study. (b) Childhood ALL.
Table 3 Multivariate cox model for disease-free survival
Feature Univariate analysis Multivariate analysis
P-value P-value
Global series
ASPP1 hypermethylation 0.0003 0.007
WBC>50000 109/l 0.0006 0.05
BCR-ABL positivity 0.0009 0.002
T phenotype 0.0008 NS
Age o15 years o0.0001 0.0001
PETHEMA poor risk 0.05 NS
Chilhood ALL
ASPP1 hypermethylation 0.01 0.01
T phenotype 0.05 NS
WBC>50000 109/l 0.05 NS
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While this manuscript was under preparation Liu
et al. (2005) described in three cell lines from breast
cancer and hepatocarcinoma that downregulation of
ASPP1 and ASPP2 was associated with abnormal
methylation of their promoters. We did not find an
abnormal methylation of the ASPP2 promoter either in
ALL or CML cells, although ASPP1 was hypermethy-
lated in a significant percentage of patients with ALL.
Other mechanisms of ASPP1 and ASPP2 silencing may
exist. Although so far mutations of either of the two
genes have not been described, we observed in CML
cells from patients that a significant percentage of them
have a reduced expression of ASPP1 that is not
associated with hypermethylation of the promoter,
suggesting that other mechanisms may be involved in
the regulation of ASPP proteins (unpublished observa-
tions).
In conclusion, our results suggest a role for ASPP1 in
the pathogenesis of ALL and establish methylation and
expression of ASPP1 as independent prognostic factors
for patients with ALL. Our study also indicates that
ASPP1 expression is at least partially regulated by
epigenetic mechanisms such as gene promoter methyla-
tion and supports a role for ASPP members in the
pathogenesis of ALL as a means by which ALL cells can
escape apoptosis despite the presence of wild-type p53.
Material and methods
Cell lines
We studied seven ALL-derived cell lines (TOM-1, MY,
NALM-20, LOUCY, TANOUE, JOURKAT and MOLT-4),
five chronic myeloid leukemia (CML) (BV173, TCC-S,
KU812, KYO-1, K562), 30 breast cancer-derived cell lines
and 69 lung carcinoma-derived cell lines (see Supplementary
information for description). All cell lines were maintained in
culture in the corresponding media until harvested for DNA
and RNA extraction.
Patients and samples
Bone marrow was obtained from 180 consecutive patients (110
male; 70 female) who were diagnosed with de novo ALL
between January 1990 and December 2002 after informed
consent had been obtained from the patient or the patient’s
guardians. The median age at diagnosis of the study
population was 14 years (range, 0.5–82 years). Of these
patients, 88 were children (median age 5 years; range 0.5–14
years) and 92 adult ALL (median age 29 years; range 15–82
years). Diagnosis was established according to standard
morphologic, cytochemical and immunophenotypic criteria.
Patients were studied at the time of initial diagnosis; were risk-
stratified according to the therapeutic protocol, which was
always based on recognized prognostic features (including
cytogenetics); and were entered in ALL protocols of the
PETHEMA Spanish study group. For statistical analyses,
children were also grouped according to the National Cancer
Institute (NCI) risk-classification criteria (Smith et al., 1996).
The specific PETHEMA ALL treatment protocols in which
these patients entered included ALL-89 (between 1990 and
1993; n¼ 50) and ALL-93 (between 1993 and 2002; n¼ 130).
The design and results of these studies have been reported
previously (Ribera et al., 1998, 2002; Ortega et al., 2001). A
total of 66 patients relapsed. In all, 27 patients received stem
cell transplantation (seven autologous, 20 allogeneic) in the
first (n¼ 10) or second complete remission (CR) (n¼ 17).
There are 100 patients currently alive. Clinical characteristics
of the patients are listed in Table 1.
Quantitative real-time PCR (Q-RT-PCR)
Total RNA was extracted from mononuclear marrow cells or
cell lines with Ultraspec (Biotecx, Houston, TX, USA)
following the manufacturer’s instructions. Reverse transcrip-
tion was performed on 1 mg of total RNA, after heating at
701C for 5min, with random hexamers as reaction primers.
The reaction was carried out at 421C for 45min in the presence
of 12U Avian Myeloblastosis virus reverse transcriptase
(Boehringer-Mannhein, Germany). Q-RT-PCR was per-
formed in a rapid fluorescent thermal cycler with three-color
fluorescence monitoring capability (LightCycler, Roche Mo-
lecular Biochemicals, Mannheim, Germany), using 1ml of
cDNA in 20 ml reaction volume with 0.4mmol/l of each primer,
and 2ml of 10 LightCycler FastStar DNA Master SYBR
Green I (Roche Molecular Biochemicals, Mannheim, Ger-
many). The final Mg2þ concentration in the reaction mixture
was adjusted to 3.5mmol/l. Primer set was specific for the
ASPP1 (Homo sapiens protein phosphatase 1, regulatory
(inhibitor) subunit 13B (PPP1R13B), mRNA, GeneBank:
NM_015316; sense, 50-TTGTCCTCTCATTGCACG-30; anti-
sense, 50-AACTTACCCTCTCAGAGC-30), ASPP2 (tumor
protein p53 binding protein, 2 (TP53BP2), mRNA, Gene-
Bank: NM_005426; sense, 50-GTGCTGCCTCATGTAACA
AC-30; antisense, 50-TATGCCCATCTTCTCCTGAAC-30) or
iASPP (PPP1R13L, mRNA, GeneBank: NM_006663; sense,
50-AGAGAGCGTACACTGC-30; antisense, 50-GCAACGAC
ACAGTCATC-30). The following program conditions were
applied for Q-RT-PCR running: denaturation program,
consisting in one cycle at 951C for 8min; amplification
program, consisting in 45 cycles at 951C for 5 s, 601C for 10 s
and 721C for 15 s; melting program, one cycle at 951C for 0 s,
401C for 60 s and 901C for 0 s; and cooling program, one cycle
at 401C for 60 s. The temperature transition rate was 201C/s,
except in the melting program, which was 0.41C/s between 40
and 901C.
Amplification of ABL1 gene transcripts was performed to
assess RNA integrity and as a reference gene (forward, 50-
CCCAACCTTTTCGTTGCACTGT-30; reverse, 50-CGGCTC
TCGGAGGAGACGTAGA-30). It was amplified in the same
run and following the same procedure described above for
ASPP1. In order to reduce the variation between different
assays and samples, a procedure based on the relative
quantification of target genes vs their controls in relation to
the reference gene was used. Calculations were automatically
performed by LightCycler software (RealQuant, version 1.0,
Roche Molecular Biochemicals, Mannheim, Germany). The
normalized ratio was obtained from the next equation and
expressed as a percentage of the control:
Normalised ratio ðNASPPÞ ¼ðEtargetÞDCp target ðcontrolsampleÞ
 ðErefÞDCp ref ðcontrolsampleÞ
Efficiencies (E) for each gene were calculated from the slopes
of crossover points (Cp) vs cDNA concentration plot,
according to the formula E¼ 10(1/slope). DCp corresponds to
the difference between control Cp and sample Cp, either for
the target or for the reference genes. The selected control was a
bone marrow specimen from a healthy donor and was
considered as 100% expression. Occasionally, equal amounts
of PCR products were separated on a 2% agarose gel, stained
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with ethidium bromide and visualized under UV light. Similar
procedures were employed for analyzing ASPP2 and iASPP
expression.
To determine the cutoff point for abnormal ASPP1
expression in ALL samples, the NASPP1 value was determined
in 20 bone marrow samples from healthy donors. The NASPP1
value for ASPP1 falls between 107 and 86% (mean:
9376.6%). A NASPP1 value below 60% (determined as the
mean minor 5 s.d.) was chosen to define underexpression of
ASPP1 in ALL RNA samples. Following the same experi-
ment, a value below 60% was also considered to define
underexpression of both ASPP2 and iASPP genes.
Methylation-specific PCR
DNA of all cell lines and primary tumors was extracted using
QIAmp DNA Mini Kit (Qiagen, Hilden, Germany). We used
an methylation-specific PCR (MSP) technique to analyze and
determine the methylation status of ASPP1 and ASPP2
promoter region (GeneBank: NM 015316 and NM 005426).
MSP is based on a bisulfite treatment of the DNA that
modifies unmethylated but not methylated cytosines into
uracils. Subsequent PCR using primers specific to sequences
corresponding to either methylated or unmethylated DNA
were performed. 1 mg of genomic DNA was treated and
modified using the CpGenomict DNA Modification Kit
(Intergen Company, Purchase, NY, USA). Bone marrow
DNA from healthy donors was used as a negative control and
human male genomic DNA universally methylated for all
genes (Intergen Company, Purchase, NY, USA) was used as a
positive control for methylation-specific assays. PCR reactions
for ASPP1-MSP and ASPP2-MSP were carried out in a total
volume of 25ml, using 3 ml of modified DNA, 1U AmpliTaq
Gold DNA Polymerase (Applied Biosystems, Foster City, CA,
USA), 1.5mM MgCl2, 0.2mM dNTPs and 50 pmol of each
primer. For ASPP1-MSP, ASPP1-1 (50-AAGTAGGTGTTA
GTTAAGGGCGTC-30) and ASPP1-2 (50-ACCGACTATAA
ACCGAAAACGT-30) primers were used for the methylated
reaction, which amplify a 205 bp product and ASPP1-3 (50-AA
GTAGGTGTTAGTTAAGGGTGTTG-30) and ASPP1-4
(50-AAACCAACTATAAACCAAAAACATC-30) primers for
the unmethylated reaction, which amplify a 207 bp product.
For ASPP2-MSP were used ASPP2-1 (50-ATTTTGTTTAC
GCGTTTAACGTC-30) and ASPP2-2 (50-GAAACAATTAA
AAAACCGCG-30) primers for the methylated reaction, which
amplify a 164 bp product and ASPP2-3 (50-ATTTTGTTTA
TGTGTTTAATGTTGG-30) and ASPP2-4 (50-CAAAACA
ATTAAAAAACCACACC-30) primers for the unmethylated
reaction, which amplify a 165 bp product. PCR conditions for
ASPP1-1/ASPP1-2 and ASPP2-1/ASPP2-2 primers were 941C
for 10min, followed by 35 cycles at 941C for 1min, 591C for
1min and 721C for 1min; ASPP1-3/ASPP1-4 and ASPP2-
3/ASPP2-4 primers conditions were 941C for 10min, followed
by 35 cycles at 941C for 1min, 551C for 1min and 721C for
1min. The final extension was at 721C for 10min in both cases.
MSP products were separated on a 2% agarose gel, stained
with ethidium bromide and visualized under UV light. Results
were confirmed by repeating bisulfite treatment and MSP
assays for all samples.
MSP product sequencing
Amplification products obtained in MSP reactions were
subcloned into pCRs 4-TOPOs plasmid using TOPO TA
Clonings Kit for Sequencing (Invitrogen Life Technologies,
Paisley, UK) and transformed into Escherichia coli according
to the manufacturer’s recommendations. Colonies with re-
combinant plasmids containing the described PCR products
were screened by digestion with EcoRI (Amersham Bios-
ciences, Buckinghamshire, UK). Candidate plasmid clones
were sequenced with ABI-PRISMt d-Rhodamine Terminator
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA)
in an ABI PRISMt 377 DNA Sequencer (Applied Biosystems,
Foster City, CA, USA) using T7 and T3 universal forward and
reverse primers.
Treatment with a demethylating agent 5-Aza-20-deoxycytidine
ALL-derived TOM-1, NALM-20 and MY cell lines were
grown at a density of 600 000 cells/ml in 25 cm2 flasks with
10ml of RPMI 1640 medium supplemented with 20% fetal
bovine serum and maintained at 371C in a humid atmosphere
containing 5% CO2. Each cell line was treated with 2 and 4mM
of 5-Aza-20-deoxycytidine (Sigma-Aldrich, Steinheim, Ger-
many) for 4 days. After treatment, cells were washed in PBS,
pelleted by centrifugation at 1500 r.p.m. during 5min and used
for genomic DNA and RNA isolation. DNA was extracted
using QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) and
total RNA using Rneasys Mini Kit (Qiagen, Hilden,
Germany). Of total RNA, 1 mg was used for cDNA synthesis
using SuperScriptt II RNase H-RT (Invitrogen Life Technol-
ogies, Paisley, UK) with random hexamers.
FISH analysis
Detection of ASPP1 and TP53 deletion was performed by
FISH in ALL-derived TOM-1, NALM-20, MY, LOUCY and
TANOUE cell lines. FISH analysis for ASPP1 was performed
with RP11-73M18 BAC clone that covers the ASPP1 gene,
RP11-600F24 BAC clone centromeric to ASPP1 that covers
the MARK3 gene and an alphoide probe that covers the
chromosome 14 and 22 centromeres. TP53 FISH analysis was
performed with RPCI-11 199F11 BAC clone (located on
17p13.1) and one alphoide probe that covers the chromosome
17 centromere. These clones were identified by the Human
Genome Project Working Draft of the University of California
at Santa Cruz (http://genome.ucsc.edu) and by the National
Center for Biotechnology Information (http://www.ncbi.nlm.-
nih.gov). The clones were obtained from the Children’s
Hospital Oakland Research Institute (http://www.chori.org/
bacpac/home.htm). All DNA probes were prepared with a
QIApreps Spin Miniprep Kit (Qiagen, Hilden, Germany). For
ASPP1 FISH analysis, RP11-73M18 BAC DNA was labeled
with Spectrum Oranges-dUTP, RP11-600F24 with Spectrum
Greens-dUTP and alphoide DNA with diethylaminocoumar-
in-5-dUTP (DEAC) (Vysis, Downers Grove, IL, USA) by nick
translation with a Nick Translation Mix (Roche Molecular
Biochemicals, Mannheim, Germany). For TP53, RPCI-11
199F11 BAC DNA was labeled with Spectrum Oranges-dUTP
and alphoide DNA with Spectrum Greens-dUTP (Vysis,
Downers Grove, IL, USA). Chromosomes were identified
using counterstaining with 40,6-diamidino-2-phenylindoledihy-
drochloride and 1,4-diazabicicle-(2.2.2)-octane (DAPI-Anti-
fade) (Appligene Oncor, Ilkirch, France). The slides were
analyzed with an Axioplan 2 Imaging fluorescence microscope
(Zeiss, Go¨ttingen, Germany) and digital images were collected
using a CCD camera and analyzed by the in situ imaging
system 3.4.0. software (Metasystem, Altlussheim, Germany).
Analysis of TP53 mutations and methylation
We analyzed exons 5–8 of TP53 gene by DGGE, a highly
sensitive technique to scan for mutations, and exons 1–4 and
9–11 of TP53 by direct sequencing in ALL-derived TOM-1,
NALM-20, MY, LOUCY and TANOUE cell lines. Primer
sequences, PCR and DGGE conditions used for each TP53
exon were those described by Agirre et al. (2002) for exon 1–5
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and 9–11, Borresen et al. (1991) for exons 7 and 8 and by
Hamelin et al. (1993) for exon 6. Negative controls (wild-type
samples) and positive controls (known mutants) were included
in each experiment. Fragments showing an altered migration
pattern with respect to the wild-type control in a DGGE
analysis were subjected again to the complete procedure in
order to confirm the initial results. Those fragments with at
least two repeated aberrant patterns were purified from the
initial PCR reactions and both strands were sequenced with
fluorescence labeled chain terminators in an ABIPRISM 377
DNA sequencer (Applied Biosystems, Foster City, CA, USA).
For methylation analysis, genomic DNA was completely
digested with methylation-sensitive restriction enzymes Hpa II
(for CpG dinucleotides) and Eco RII (for CCWGG motifs),
and then amplified by PCR (Agirre et al., 2003). In these
assays, unmethylated sites are digested and cannot be
amplified, whereas the presence of a methylated cytosine
prevents digestion and results in successful amplification.
Digestion controls were performed with Msp I and BstN I,
which recognize the same sites as Hpa II and Eco RII,
respectively, but are methylation-insensitive. This analysis was
realized in ALL-derived TOM-1, NALM-20, MY, LOUCY
and TANOUE cell lines and in a positive control. Digestion
and PCR conditions used were as described (Agirre
et al., 2003).
Statistical analysis
P-values to compare the continuous variables between groups
of patients were two-tailed and based on the Wilcoxon rank
sum test. P-values for dichotomous variables were based on
the Fisher exact test. The remaining P-values were based on
the Pearson w2. Overall survival (OS) was measured from the
day of diagnosis until death from any cause and was only
censored for patients known to be alive at last contact.
Disease-free survival (DFS) was measured from the day that
complete response (CR) was established until either relapse or
death without relapse, and it was only censored for patients
who were alive without evidence of relapse at the last follow-
up. Distributions of OS and DFS curves were estimated by the
method of Kaplan and Meier with 95% confidence intervals
calculated using Greenwood’s formula. Comparisons of OS or
DFS between groups were based on the log-rank test.
Comparisons adjusted for significant prognostic factors were
based on Cox regression models and hazard regression models.
All relapse and survival data were updated on March 31, 2005
and all follow-up data were censored at this point.
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